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RAS signaling plays a key role in controlling appropriate cell responses to extracellular stimuli and participates in early and late devel-
opmental processes. Although enhanced ﬂow through this pathway has been established as a major contributor to oncogenesis, recent
discoveries have revealed that aberrant RAS activation causes a group of clinically related developmental disorders characterized by facial
dysmorphism, a wide spectrum of cardiac disease, reduced growth, variable cognitive deﬁcits, ectodermal and musculoskeletal anoma-
lies, and increased risk for certain malignancies. Here, we report that heterozygous germline mutations in CBL, a tumor-suppressor gene
that is mutated in myeloid malignancies and encodes a multivalent adaptor protein with E3 ubiquitin ligase activity, can underlie
a phenotype with clinical features ﬁtting or partially overlapping Noonan syndrome (NS), the most common condition of this disease
family. Independent CBLmutations were identiﬁed in two sporadic cases and two families from among 365 unrelated subjects who had
NS or suggestive features and were negative for mutations in previously identiﬁed disease genes. Phenotypic heterogeneity and variable
expressivity were documented. Mutations were missense changes altering evolutionarily conserved residues located in the RING ﬁnger
domain or the linker connecting this domain to the N-terminal tyrosine kinase binding domain, a known mutational hot spot in
myeloid malignancies. Mutations were shown to affect CBL-mediated receptor ubiquitylation and dysregulate signal ﬂow through
RAS. These ﬁndings document that germline mutations in CBL alter development to cause a clinically variable condition that resembles
NS and that possibly predisposes to malignancies.RAS signaling plays a crucial role in cell proliferation,
migration, survival, and cell fate determination and differ-
entiation and participates in early and late developmental
processes, including organogenesis, morphology determi-
nation, and growth.1 Because of its nodal role in signal
transduction, signal trafﬁc through RAS is tightly
controlled, and enhanced ﬂow through it contributes to
oncogenesis.2,3 There are activating somatic RAS gene
mutations in approximately 30% of human cancers, but
the upregulation of this signaling pathway can also result
from enhanced function of upstream signal transducers
or RAS effectors, as well as from inefﬁcient function of
feedback mechanisms. However, the recent, unpredicted
discovery of germline mutations in a number of genes en-
coding proteins involved in RAS signaling has established
a novel scenario in which aberrant signal ﬂow through
RAS is causally linked to a group of clinically related devel-
opmental disorders, namely the neuro-cardio-facial-cuta-
neous syndromes (NCFCS), or RAS-opathies.3–5
Noonan syndrome (NS [MIM 163950]), the most
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cardiac disease, reduced postnatal growth, and ectodermal
and skeletal defects.6–8 Distinctive NS facial features
consist of a broad forehead, hypertelorism, down-slanting
palpebral ﬁssures, and low-set, posteriorly rotated ears.
Additional, relatively recurrent features include a webbed
and/or short neck, variable cognitive deﬁcits, cryptorchi-
dism, lymphatic dysplasias, bleeding tendency, and,
rarely, predisposition to childhood hematologic malig-
nancies, particularly juvenile myelomonocytic leukemia
(JMML [MIM 607785]). NS is genetically heterogeneous,
and mutations in the PTPN11 (MIM 176876),9 SOS1
(MIM 182530),10,11 KRAS (MIM 190070),12,13 NRAS
(MIM 164790),14 RAF1 (MIM 164760),15,16 BRAF (MIM
164757),17 SHOC2 (MIM 602775),18 and MAP2K119
(MIM 176872) genes have been documented to account
for 70%–75% of affected individuals. These genes encode
transducers that positively contribute to RAS-MAPK
signaling. Although some (i.e., NRAS, KRAS, and BRAF)
had previously been recognized as proto-oncogenes, the
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Figure 1. Germline CBL Mutations Underlying Noonan Syndrome and Related Phenotypes
(A) Location of predicted amino acid substitutions associated with disease is shown below the CBL structure scheme. CBL comprises an
N-terminal tyrosine kinase binding domain (TKB) connected by a linker to the RING-ﬁnger domain (RING) implicated in E2 enzyme
binding. These domains are followed by a proline-rich region and a C-terminal portion containing sites of tyrosine phosphorylation
(not shown) and a sequence homologous to both the ubiquitin-associated and leucine zipper domain (UBA/LZ). Numbers above the
domain structure indicate the amino acid boundaries of those domains.
(B) Electropherograms showing the identiﬁed heterozygous missense mutations.
(C) Mutated amino acid residues in the three-dimensional structure of human CBL complexed with UBE2L3.40 Ca ribbon trace of the
CBL tyrosine kinase binding domain (cyan), linker (orange), and RING-ﬁnger domain (red) of CBL are shown together with the inter-
acting portion of UBE2L3 (gray). Mutated residues are indicated with their side chains as blue sticks. Residues of the linker and RING
domain interact with the tyrosine kinase binding domain (orange and red respectively) or bind UBE2L3 (green and yellow, respectively);
their side chains are also shown. Visualization and analysis of themolecular structure was performed with the programUCSF Chimera.54
(D) Facial features of the affected subjects carrying the c.1100A>C (Gln367Pro), c.1144A>G (Lys382Glu), c.1168G> T (Asp390Tyr) (at
5 years and 15 years), and c.1259G > A (Arg420Gln) (father and daughter) mutations.the discovery of PTPN11’s involvement in leukemogen-
esis.20,21 Here, we provide evidence that germline muta-
tions in the Cas-Br-M (murine) ecotropic retroviral trans-
forming sequence (CBL [MIM 165360]) gene, which
encodes a multivalent adaptor protein with an established
role in myeloid malignancies, can underlie a clinically
variable condition with features ﬁtting or partially over-
lapping NS.
CBL is a member of a small family of E3 ubiquitin ligases
that negatively regulate intracellular signaling down-
stream of receptor tyrosine kinases (RTKs), but it also
contributes to signal trafﬁc through its adaptor function.22
CBL is ubiquitously expressed and characterized by an
N-terminal tyrosine kinase-binding (TKB) domain that is
involved in protein-protein interaction and is connected
by a short linker to a zinc-binding RING-ﬁnger domain
mediating the E3 ubiquitin ligase activity (Figure 1A).
The C-terminal portion of the protein includes an exten-The Americsive proline-rich region containing a number of putative
SH3-binding motifs, and this region is followed by
multiple SH2-binding tyrosine phosphorylation sites and
a ubiquitin-associated (UBA) domain overlapping with
a leucine zipper (LZ) motif involved in ubiquitin binding
and protein dimerization, respectively.23 CBL mediates
the conjugation of ubiquitin to activated RTKs; this
conjugation is required for receptor internalization, endo-
cytic sorting, and switching off signaling via receptor
degradation or recycling.24 Somatically acquired, mostly
homozygous CBL mutations have recently been found to
occur with variable prevalence in myeloproliferative disor-
ders, including JMML, and myeloid leukemias.25–33 They
are largely small in-frame deletions or missense changes
affecting the RING-ﬁnger domain and/or the adjacent
linker region, and they appear to act in a dominant-nega-
tive fashion by uncoupling CBL binding to activated
RTKs from their ubiquitylation and degradation.an Journal of Human Genetics 87, 250–257, August 13, 2010 251
Given the link between the functions of CBL and RAS,34
CBL’s ubiquitous expression, and the negative modulatory
role on signaling elicited by several RTKs—including the
epidermal growth factor receptor (EGFR [MIM 131550])—
that have roles in developmental processes,35–37 as well as
the contribution of impaired CBL function to leukemogen-
esis, particularly JMML, we hypothesized that this gene
might be implicated in the pathogenesis of NS or related
phenotypes. Three hundred and sixty-ﬁve subjects with
NS or a phenotype suggestive of this disorder and without
mutation inmost of the previously identiﬁed disease genes
(M.T., B.D., C.R., M.Z., and H.Y., unpublished data) were
included in the study. The clinical features inmost individ-
uals satisﬁed the diagnostic criteria for NS,8 but subjects
lacking sufﬁcient characteristics to allow a deﬁnitive diag-
nosis were also considered. DNA samples and clinical data
were collected under researchprojects approved by an insti-
tutional review board, and informed consent for genetic
analyses was obtained from all subjects included in the
study. Genomic DNA was isolated from peripheral blood
leukocytes, and the entire CBL coding sequence
(NM_005188.2) was scanned for mutations. Primer pairs
designed to amplify exons and their intron boundaries are
listed in Table S1. PCR ampliﬁcations were carried out
with the high-ﬁdelity Optimase Polymerase (Transge-
nomic) at conditions indicated byOptimase ProtocolWriter
software (Transgenomic). Mutation analysis of the am-
plimers was performed via denaturing high-performance
liquid chromatography (DHPLC) with the Wave 2100
System (Transgenomic) at column temperatures recom-
mended by Navigator software, version 1.6.4.12 (Transge-
nomic). Amplimers with abnormal denaturing proﬁles
were puriﬁed (Microcon PCR [Millipore]) and then
sequenced bidirectionally with the ABI BigDye Terminator
Sequencing Kit v.1.1 (Applied Biosystems) and ABI Prism
3100 and 3730 Genetic Analyzers (Applied Biosystems).
Mutation analysis allowed the identiﬁcation of heterozy-
gosity for aCBLmutation in four unrelated individuals (Fig-
ure 1B). The c.1100A > C, c.1144A > G and c.1168G > T
missense changes, predicting the Gln367Pro, Lys382Glu,
and Asp390Tyr amino acid substitutions, respectively,
were identiﬁed in three apparently sporadic cases. Parental
DNA sequencing of the relevant exon demonstrated the de
novo origin of the c.1100A > C and c.1168G > T transver-
sions, and STR genotyping (AmpF/STR Identiﬁer PCR
Ampliﬁcation Kit [Applied Biosystems]) conﬁrmed pater-
nity. In these cases, the defects were documented in hair
bulb (c.1168G > T) and buccal epithelial (c.1100A > C
and c.1168G> T) cell specimens, which excluded a somatic
event restricted to hematopoietic cells (Figure S1A available
online). In case BO5149, the c.1144A>Gchangewas docu-
mented as having been inherited from the father, who was
originally deemed unaffected. Review of his clinical status,
however, revealedminor signs andChiari type 1malforma-
tion (see below), the latter known to recur inNCFCS,which
suggested markedly variable expressivity of the mutation.
In the family transmitting the trait, the c.1259G> A transi-252 The American Journal of Human Genetics 87, 250–257, August 1tion, predicting the Arg420Gln substitution, cosegregated
with disease. The inherited c.1144A > G and c.1259G > A
changes were unobserved in more than 400 population-
matched unaffected individuals scanned by DHPLC anal-
ysis and direct sequencing, strongly arguing against the
possibility that these variants were disease-unrelated poly-
morphisms occurring in the population. As expected, the
two de novo CBL missense changes were not observed in
the controls, further evidence that these variants were
mutations.
The four mutations affected residues evolutionarily
conserved in CBL orthologs and paralogs (Figure S1B)
that were located within the RING ﬁnger domain
(Lys382, Asp390, and Arg420) or the adjacent linker con-
necting this domain to the N-terminal TKB domain
(Gln367), a region that is known to represent the muta-
tional hot spot for somatically acquired lesions occurring
in malignancies.25–27,29–32,38,39 According to the crystal
structure of the TKB-linker-RING portion of CBL com-
plexed with the ubiquitin-conjugating enzyme E2L
3 (UBE2L3 [MIM 603721]),40 Lys382 and Arg420 are posi-
tioned on the RING surface involved in binding to UBE2L3
(Figure 1C). These residues are adjacent or close to four of
the invariant cysteine residues that participate in the stabi-
lization of the domain structure by binding the two tetra-
hedrally coordinated zinc ions. Lys382 is adjacent to resi-
dues involved in UBE2L3 binding, and Arg420 directly
participates in this binding network. Missense mutations
affecting Arg420, including the Arg420Gln substitution,
or residues ﬂanking Lys382 (Leu380, Cys381, Ile383, and
Cys384) had previously been documented in chronic mye-
lomonocytic leukemia (CMML) and acute myeloid
leukemia (AML) (Figure S2).26,27,30–32,38,39 On the other
hand, Asp390 is adjacent to a residue (Lys389) contrib-
uting to the intramolecular interaction involving the
linker and RING domain with the TKB domain, which is
critical for proper CBL function.40,41 Consistent with the
hypothesis that the Asp390Tyr substitution affects the
integrity of the RING-TKB interface, a missense change
(Asp390Val) altering Asp390 has been reported in myeloid
malignancies.39 Similarly, Gln367 is located in a region of
the linker that includes residues contributing to the
intramolecular interaction with the TKB domain and
UBE2L3 binding (Figure 1C).40 The Gln367Pro substitu-
tion and a nonconservative amino acid change Gln367Lys
affecting the same residue have been identiﬁed in
CMML.31
Detailed clinical information was obtained for the six
identiﬁed subjects harboring CBL mutations (Figure 1D).
The patient heterozygous for the c.1100A> C transversion
(NMC-NS076) was referred because of developmental
delay and congenital heart disease. His parents were non-
consanguineous, apparently healthy, and had no features
suggestive for NS. Clinical examination at 9 years showed
a triangular face with hypertelorism, mild palpebral ptosis,
as well as large, slightly low-set ears. He had normal
stature, a thorax with widely spaced nipples, and pectus3, 2010
excavatum. He had several cafe´-au-lait spots, but no other
ectodermal abnormalities were apparent. Cardiologic eval-
uation revealed an enlarged left atrium and transient
chaotic ventricular dysrhythmias, an uncommon feature
in NS. A head MRI scan showed delayed myelinization
without structural abnormalities. Overall, his features
were suggestive of NS but did not fulﬁll the clinical criteria
for a deﬁnitive diagnosis.
The child heterozygous for the de novo c.1168G > T
transversion (case ISS-S1N51) was initially referred at age
3 years. She displayed an unusual facial appearance
(frontal bossing, wide nasal bridge, low-set and posteriorly
rotated ears, and mild left-sided ptosis) and mild global
developmental delay. She had generalized hypotonia in
the newborn and infancy periods and severe feeding prob-
lems. Her early milestones were delayed; she achieved
walking at age 21 months and had signiﬁcant language
delay. There was no organomegaly, and her cardiovascular
system was normal. Clinical examination at 5 years
showed still slightly delayed speech but improved motor
skills. There was mild ectodermal involvement; she had
ﬁne and sparse scalp hair, widely spaced nipples, and
a mild pectus excavatum anteriorly. Her height was at
the tenth percentile. She had joint laxity at the elbows,
shoulders, and ﬁngers. At 15 years, dysmorphic features
appeared less evident, and growth and IQ were in the
normal range, but she continued to have low muscle
tone generally and hyperextensible joints.
The subject inheriting the c.1144A > G substitution
(case BO5149) was an 18-year-old girl who fulﬁlled the
clinical criteria for the diagnosis of NS, exhibiting short
stature (<3rd percentile), distinctive facial features (hyper-
telorism, ptosis, downslanting palpebral ﬁssures, epican-
thal folds, and low-set, posteriorly rotated ears), a short
neck with a marked pterigium colli, and a low posterior
hairline. She presented with a bicuspid aortic valve with
stenosis requiring surgical intervention. Other features
included strabismus, thorax anomalies, cubitus valgus, hy-
perextensible joints, conductive hearing loss, and unilat-
eral renal agenesis. Her 46-year-old father, who carried
the missense change, did not show signiﬁcant dysmorphic
facial features, had a normal height, and showed no
evidence of relevant cardiovascular and skeletal anomalies.
He did have, however, a broad neck, low posterior hairline,
and a Chiari type 1malformation, a feature recurring in NS
and clinically related disorders,42–45 that was complicated
by tri-ventricular hydrocephalus and cervical syringomy-
elia resulting in weakness and hyperreﬂexia of the legs,
sensory deﬁcits of the trunk and lower right limb, and
nystagmus, which required decompressive suboccipital
craniectomy and cervical laminectomy.
At six months of age, the girl (case HD316) inheriting
the c.1259G > A transition from her affected father had
a coarse, dysmorphic face (epicanthal folds, ﬂat nasal
bridge, thick lips, dysmorphic ears with thick helices, and
a mid-face angioma). She had a short neck with redundant
skin, thin hair, dysplastic toenails, dark skin, cafe´-au-laitThe Americspots and streaks on the legs, and muscular hypotonia.
Growth was in the normal range. Echocardiography re-
vealed mild-to-moderate mitral valve insufﬁciency due to
dysplastic leaﬂets. At 8 years of age, facial features and
signs included pale-blue eyes, long philtrum, a thick and
everted lower lip, and dysmorphic ears. Her hair was
thin, dysplastic, and slow growing, and her eyebrows
were sparse. Her neck was short, and her chest was broad
with wide-spaced nipples. Her skin appeared dark and
dry, and she had eczematous lesions on the face, keratosis
pilaris, and cafe´-au-lait streaks and spots on her legs. Her
joints were hypermobile, and her voice was hoarse. Cogni-
tive development was mildly delayed. A head MRI showed
an abnormal corpus callosum with enlargement of the
anterior portion and hypoplasia of the posterior region,
as well as cerebellar vermis hypoplasia, the latter represent-
ing, to our knowledge, an unreported feature in NCFCS.
Her 40-year-old father showed a high forehead, sparse
eyebrows, down-slanting palpebral ﬁssures, thick lips,
thick helices, a short neck, a broad chest, pectus excava-
tum, and dry and dark skin with hyperpigmented lesions
in the sacral region. Bilateral cryptorchidism was operated
upon at 8 years of age. Developmental milestones were
achieved normally, but learning difﬁculties were recorded.
None of the six subjects heterozygous for a CBL mutation
exhibited any hematologic anomaly or malignancy.
To explore the consequences of the identiﬁed mutations
on CBL ubiquitin ligase activity as well as their effects on
RAS signal output, we transiently expressed HA-tagged
Asp390Tyr and Arg420Gln CBLmutants in COS-1 cells and
evaluated the levels of EGFR ubiquitylation and the extent
of signal ﬂow through the MAPK and PI3K-AKT cascades
(Figure 2). Thesemutations were selected as representatives
of the two classes of lesions affecting residues located at the
interface between the TKB and RING-ﬁnger domains
(Gln367Pro and Asp390Tyr) or facing toward the E2 ubiq-
uitin-conjugating enzyme (Lys382Glu and Arg420Gln).
Compared to that of the wild-type CBL protein, expression
of each mutant resulted in impaired receptor ubiquityla-
tion in response to EGF stimulation. These ﬁndings are
in line with previous studies focused on leukemia-associ-
ated CBL mutations, indicating that these lesions impair
CBL ubiquitin ligase function, weaken CBL-mediated
degradation of cell-surface receptors, and have a domi-
nant-negative effect on the wild-type protein.26,31 Tran-
sient expression of each mutant was shown to enhance
AKT phosphorylation basally, possibly because of inefﬁ-
cient CBL-mediated downregulation of cell-surface recep-
tors. Cells expressing the Arg420Gln mutant also showed
constitutive ERK phosphorylation. Overall, our ﬁndings
indicate that germline disease-associated CBL mutations
dysregulate intracellular signaling through RAS and that
this effect is due, at least in part, to impaired receptor ubiq-
uitylation. These results are consistent with the available
data on leukemia-associated CBL mutants.
Mutations of genes coding for transducers implicated in
RAS-MAPK signaling have recently been recognized as thean Journal of Human Genetics 87, 250–257, August 13, 2010 253
Figure 2. Functional Consequences of
the Disease-Causing Asp390Tyr and
Arg420Gln CBL Mutant Proteins
(Left) EGFR ubiquitylation in COS-1 cells
transiently expressing the Asp390Tyr,
Arg420Gln, and wild-type CBL proteins
after EGF stimulation (100 ng/ml, 1 hr).
EGFR ubiquitylation (anti-ubiquitin, Santa
Cruz Biotech, sc-8017) was determined on
immunoprecipitated EGFR (Cell Signaling,
#4267). Immunoprecipated EGFR, and
expression levels of exogenous CBL (anti-
HA antibody, Sigma, H3663) and EGFR
proteins and b-actin (Sigma, A5441) in cell lysates are also shown. Blots are representative of three experiments performed.
(Right) AKT and ERK phosphorylation assays in COS-1 cells transiently expressing the Asp390Tyr, Arg420Gln, and wild-type CBL
proteins. Protein phosphorylation status (pAKT, Cell Signaling, #9271; pERK1/2, Cell Signaling, #9106) was evaluated in time-course
experiments basally or after EFG stimulation. AKT (Cell Signaling, #9272), ERK1/2 (Cell Signaling, #9102) and CBL (anti-HA, see above)
expression levels are also shown.molecular cause underlying a group of clinically related
developmental disorders of which NS represents the most
recurrent condition. These Mendelian traits are caused by
mutations in genes encoding RAS proteins (KRAS, HRAS,
and NRAS), downstream transducers (RAF1, BRAF,
MAP2K1, andMAP2K2 [MIM 601263]), or pathway regula-
tors (PTPN11, SOS1, NF1 [MIM 613113], SPRED1 [MIM
609291], and SHOC2). Here, we report that germline
missense mutations affecting the linker region or the
RING ﬁnger domain of CBL, a known negative regulator
of activated RTKs, can underlie a condition resembling
NS or conditions with clinical features partially overlap-
ping it, and we thereby identify a previously unpredicted
consequence of dysregulated CBL function in human
disease. One mechanism by which intracellular signaling
is switched off is RTK downregulation through receptor
internalization and degradation. CBL contributes to this
process as an adaptor molecule with ubiquitin ligase
activity.23 It has been shown that direct or GRB2-mediated
binding of CBL to EGFR is required for multiple mono-
ubiquitylation of the activated receptor. Ubiquitylation
of EGFR is followed by its internalization in clathrin-
coated vesicles that fuse with internal vesicles to form
endosomes, from where ubiquitylated EGFR is sorted to
lysosomes for degradation while nonubiquitylated EGFR
is recycled back to the plasma membrane. In this process,
CBL function is required in the sorting step for efﬁcient
EGFR downregulation.46,47 On the basis of these consider-
ations, mutations impairing the ubiquitin ligase activity of
CBL are expected to promote enhanced intracellular signal
ﬂow through inefﬁcient receptor degradation, which is
consistent with the present ﬁndings and recently pub-
lished data.26,31 Hinting at the present ﬁndings, acquired
CBL mutations affecting the RING-ﬁnger domain and the
adjacent linker stretch had been shown to contribute to
the pathogenesis of myeloid leukemias and myeloprolifer-
ative disorders, including JMML. In JMML, CBLmutations
are largely missense; residue Tyr371 is mutated in the
majority of cases.27,29 These lesions are mutually exclusive
from PTPN11, KRAS,NRAS, andNF1mutations, which also
occur in this myeloproliferative disorder. This ﬁnding254 The American Journal of Human Genetics 87, 250–257, August 1supports the functional equivalence of CBL defects in
causing enhanced RAS signaling, at least in precursor cells
of the myeloid lineage.27,29
Although the location and type of identiﬁed mutations
are compatible with the idea that this newly identiﬁed
condition results from the dominant-negative effect of
one mutated CBL allele, it should be considered that CBL
is also believed to regulate signaling positively, for example
as part of the MAPK and PI3K/AKT pathways, via its
adaptor function.48–50 This positive modulatory role is
attained through binding to a plethora of proteins and
functioning as a scaffold allowing the formation of multi-
protein complexes mediating signal ﬂow. Although we
cannot formally exclude effects on this still poorly charac-
terized positive modulatory function, the fact that the
disease-causing mutations are far from the known binding
sites makes this unlikely.
In JMML and other myeloid malignancies, CBL muta-
tions generally occur as homozygous lesions as a result of
acquired isodisomy, which suggests that the contribution
of a CBL mutant to leukemogenesis requires either loss of
function of the wild-type protein or increased dosage of
the mutated allele.27,31,32 Although no hematological
malignancy was documented in the six subjects carrying
a germline CBL mutation, this consideration supports the
idea that the identiﬁed heterozygous condition for a germ-
line CBLmutationmight represent a condition that predis-
poses to malignancies. A similar scenario within the
NCFCS family is observed in neuroﬁbromatosis type I
(NF1 [MIM 162200]), in which a second, somatic loss-of-
function mutation or deletion of the wild-type NF1 allele
is associated with the development of malignancies.51
NF1 is a relatively common autosomal-dominant disorder
characterized by cafe´-au-lait spots, neuroﬁbromas, Lisch
nodules, axillary and inguinal freckling, and recurrent
features comprising reduced growth, skeletal defects, deﬁ-
cits in cognitive function, and increased risk for certain
malignancies, including JMML. Similar to ﬁndings of the
present study, a markedly wide phenotypic spectrum is
associated with germline mutations in the NF1 gene;
even within the same family, some patients are mildly3, 2010
affected, and others have severe manifestations of dis-
ease. Neuroﬁbromin, the NF1 gene product, is a negative
modulator of RAS function, which partly explains the
overlap with NS in some patients and the resulting so-
called neuroﬁbromatosis-Noonan syndrome (NFNS [MIM
601321]).52,53
Although analysis of wider cohorts will be required to
characterize more precisely the phenotypic spectrum
associated with germline CBLmutations, the present ﬁnd-
ings indicate that these lesions are associated with a strik-
ingly variable phenotype and that clinical features might
be quite subtle. Several lines of evidence, however, support
the idea that the heterozygous condition for a germline
CBL mutation underlies a previously unrecognized
disorder resembling or partially overlapping NS. First,
no missense change affecting the linker region and the
adjacent RING-ﬁnger domain was identiﬁed in more
than 400 unaffected population-matched subjects. Such
a nonrandom distribution of sequence variants is statis-
tically signiﬁcant (Fisher’s exact probability < 0.05).
Second, two mutations arose de novo in the germline.
Third, the mutations altered highly conserved residues
in CBL orthologs and paralogs located in protein domains
functionally required for CBL-mediated signaling to be
properly switched off. Moreover, they overlapped in posi-
tion and, in some cases, with the precise substitution of
somatic CBL mutations observed in human cancers.
Fourth, the four germline CBL missense mutations have
functional effects on signal transduction. Previous and
present characterization of three of the mutants identiﬁed
in this study showed impairment of CBL ubiquitin ligase
activity and derangement of signaling through ERK and
AKT.
Overall, the present data indicate that CBL gene
mutations underlie a clinically variable condition that
can resemble NS phenotypically. CBL mutations are likely
to account for a small portion of subjects with features
ﬁtting NS (<1%), but they might be more common among
subjects with clinical features partially overlapping NS or
a phenotype that is suggestive of this disorder, and
particularly among subjects with NS/JMML without muta-
tions in the PTPN11, NF1, or RAS genes. These ﬁndings
provide evidence that CBL functional dysregulation can
signiﬁcantly perturb a wider range of cellular processes
than was previously known and have a direct impact on
development. Molecular genetic as well as structural and
functional data support the view that disease-associated
CBL mutations perturb intracellular signaling by affecting
receptor metabolism (i.e., recycling versus degradation)
rather than directly altering signal ﬂow at the level of
RAS or its downstream effectors, which represents the ﬁrst
evidence for disorders of the NCFCS family. Additional
work will need to provide a more precise delineation of
the phenotypic spectrum associated with germline
mutations in CBL as well as their molecular diversity and
functional consequences in intracellular signaling and
development.The AmericSupplemental Data
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